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Open access under the ElsThe antimony(III) complexes [Sb(2Fo4Ph)Cl2] (1), [Sb(2Ac4Ph)Cl2] (2) and [Sb(2Bz4Ph)Cl2] (3) were pre-
pared with N(4)-phenyl-2-formyl- (H2Fo4Ph), 2-acetyl- (H2Ac4Ph) and 2-benzoylpyridine (H2Bz4Ph)
thiosemicarbazones. The antimony(III) complexes presented antitrypanosomal activity against the epi-
mastigote and trypomastigote forms of Trypanosoma cruzi. Complexes (1) and (2) exhibited higher activ-
ity than the reference drugs benznidazole and nifurtimox.
 2010 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Parasitic diseases affect hundreds of millions people around the
world, mainly in underdeveloped countries. Since parasitic proto-
zoa are eukaryotic, they share many common features with their
mammalian host making the development of selective drugs a
hard task. Diseases caused by Trypanosomatidae, which share a
similar state regarding drug treatment, include Chagas’ disease
(Trypanosoma cruzi, T. cruzi) and leishmaniasis (Leishmania spp.).
These trypanosomatids are responsible for an infected population
of nearly 30 million and more than 400 million are at risk [1]. Cha-
gas disease, or American Trypanosomiasis, remains the major par-
asitic disease burden in Latin America, despite recent advances in
the control of its vectorial and transfusional transmission [2].
T. cruzi presents three main morphological forms. The epimasti-
gote form replicates within the crop and midgut of Chagas’ disease
vectors as it is released with the insect excrements as the non-
dividing highly infective trypomastigotes that invade mammalian
tissues via wounds caused by blood sucking action. The parasite
multiplies intracellularly as the amastigote form which is released
as the non-dividing bloodstream trypomastigote form that invades
other tissues [1].
Drugs currently used in the treatment of Chagas’ disease are
two nitroaromatic heterocycles, nifurtimox (nfx, Lampit) andx: +55 31 3409 5700.
evier OA license.benznidazole (bnz, Rochagan, Roche), introduced empirically over
three decades ago [2]. These drugs have demonstrated several lim-
itations in their use due to their low bioavailability and their lim-
ited efﬁcacy in the different stages of the disease as well as the
development of parasite resistance [3].
The pentavalent organoantimonials, meglumine antimoniate
(antimony(V) N-methyl-glucamine) and sodium stibogluconate
(sodium antimony(V) gluconate), are commonly used for the treat-
ment of leishmaniasis. The mechanism of action of the antimonial
drugs is not completely understood. It is possible that Sb(V) be-
haves as a prodrug which is probably reduced in vivo into Sb(III)
by cellular thiols and/or speciﬁc enzymes [4]. In principle anti-
mony compounds could also constitute new antitrypanosomal
drugs candidates.
Thiosemicarbazones are an interesting class of compounds with
a wide range of pharmacological applications [5] and have been
identiﬁed as lead scaffolds of cruzain inhibitors [6,7]. Cruzain
was shown to be one of the most relevant proteases in T. cruzi
[7]. In many circumstances the pharmacological action of thio-
semicarbazones increases upon coordination to metal ions [8–
10]. We demonstrated that nitro-thiosemicarbazones and their
copper(II) [11] and ruthenium(II) [12] complexes present signiﬁ-
cant in vitro anti-trypanosomal activity, the complexes being at
least 5–25 times more active than the free ligands.
We recently started an investigation on the pharmacological
proﬁle of antimony(III) complexes with thiosemicarbazones and
showed that these complexes exhibit high cytotoxicity against hu-
man leukemia cell lines [13].
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Fig. 1. Generic representation for N(4)-phenyl-2-pyridine-derived
thiosemicarbazones.
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formyl- (H2Fo4Ph), 2-acetyl- (H2Ac4Ph) and 2-benzoylpyridine
(H2Bz4Ph) thiosemicarbazones (Fig. 1) were assayed against T. cru-
zi strains. The strategy of associating thiosemicarbazones to anti-
mony(III) could lead to new metal-based anti-trypanosomal drugs.
2. Experimental
2.1. Materials and measurements
All common chemicals were purchased from Aldrich and used
without further puriﬁcation. The thiosemicarbazones were pre-
pared according to standard procedures [10].
Partial elemental analyses were performed on a Perkin–Elmer
CHN 2400 analyzer. An YSI model 31 conductivity bridge was em-
ployed for molar conductivity measurements. Infrared spectra
were recorded on a Perkin–Elmer FT-IR Spectrum GX spectrometer
using KBr plates (4000–400 cm1) and nujol mulls between CsI
plates (400–200 cm1). NMR spectra were obtained with a Bruker
DPX-200 Avance (200 MHz) spectrometer using DMSO-d6 as the
solvent and TMS as internal reference.
2.2. Syntheses of antimony(III) complexes with N(4)-phenyl-2-
formylpyridine thiosemicarbazone (H2Fo4Ph), N(4)-phenyl-2-
acetylpyridine thiosemicarbazone (H2Ac4Ph) and N(4)-phenyl-2-
benzoylpyridine thiosemicarbazone (H2Bz4Ph)
The antimony(III) complexes were obtained by mixing an etha-
nol solution (20 mL) of the desired thiosemicarbazone (1 mmol)
with antimony chloride in 1:1 ligand-to-metal molar ratio at room
temperature with stirring for 3.5 h. The resulting solids were ﬁl-
tered, washed with ethanol followed by diethyl ether, and dried
in vacuo.
2.2.1. Dichloro(N(4)-phenyl-2-formylpyridinethiosemicarbazonato)-
antimony(III) [Sb(2Fo4Ph)Cl2] (1)
Yellow solid. Anal. Calc. for C13H11Cl2N4SSb: C, 34.85; H, 2.47; N,
12.51. Found: C, 34.44; H, 2.38; N, 12.43%. FW: 447.98 g mol1. IR
(KBr, cm1): m(NAH) 3281m, m(C@N) 1611s, m(C@S) 730m, q(py)
622w. IR (CsI/nujol, cm1): m(SbANazometh.) 453m, m(SbAS) 432m,m(SbANpy) 225w, m(SbACl) 344m. 1H NMR [200 MHz, DMSO-d6, d
(ppm)] main signals: 10.40 [s, 1H, N(4)H]; 9.09 [d, 1H, H(6)];
8.09 [d, 1H, H(3)]; 8.31 [t, 1H, H(4)]; 9.16 [s, 1H, H(7)]; 7.11 [t,
1H, H(5)]. 13C NMR [200 MHz, DMSO-d6, d (ppm)] main signals:
169.12 [C(8)@S]; 151.49 [C(2)]; 147.76 [C(6)]; 140.60 [C(4)];
141.25 [C(9)]; 145.65 [C(7)@N]; 123.70 [C(5)]; 121.80 [C(3)].
KM = 20.15 O1 cm2 mol1 in DMF. Melting point: 251.9–252.4 C.
Yield 82%.
2.2.2. Dichloro(N(4)-phenyl-2-acetylpyridinethiosemicarbazonato)-
antimony(III) [Sb(2Ac4Ph)2(Cl)2] (2)
Orange solid. Anal. Calc. for C14H13Cl2N4SSb: C, 36.40; H, 2.84; N,
12.13. Found: C, 36.20; H, 2.80; N, 12.20%. FW: 461.99 g mol1. IR
(KBr, cm1): m(NAH) 3245m, m(C@N) 1596s, m(C@S) 753m, q(py)
602w. IR (CsI/nujol, cm1): m(SbANazometh.) 505m, m(SbAS) 430m,
m(SbANpy) 222w, m(SbACl) 327m. 1H NMR [200 MHz, DMSO-d6, d
(ppm)] main signals: 10.39 [s, 1H, N(4)H]; 9.09 [d, 1H, H(6)];
8.80–8.60 [d, 1H, H(3)]; 8.00–7.50 [t, 1H, H(4)]; 2.81 [s, 3H,
H(15)]; 7.11 [t, 1H, H(5)]. 13C NMR [200 MHz, DMSO-d6, d (ppm)]
main signals: 167.89 [C(8)@S]; 151.93 [C(2)]; 144.84 [C(6)];
144.47 [C(7)@N]; 142.22 [C(4)]; 120.85 [C(3)]; 139.77 [C(9)];
123.53 [C(5)]; 16.93 [C(15)]. KM = 22.79 O1 cm2 mol1 in DMF.
Melting point: 237.9–238.8 C. Yield 95%.
2.2.3. Dichloro(N(4)-phenyl-2-benzoylpyridinethiosemicarbazonato)-
antimony(III) [Sb(2Bz4Ph)Cl2] (3)
Complex (3) was obtained as previously described Ref. [13].
2.3. Crystallography
Crystals of H2Fo4PhHCl and complexes (1a) and (2) suitable for
X-ray diffraction were mounted on a glass ﬁber. Data were col-
lected at room temperature on an Oxford-Diffraction GEMINI dif-
fractometer. Final unit cell parameters were based on the ﬁtting
of all reﬂections positions. The structures were solved by direct
methods and reﬁned on F2 by full-matrix least-squares using the
SHELX-97 [14,15] program in a WinGX system [16]. All hydrogen
atoms of H2Fo4PhHCl could be identiﬁed in the Fourier difference
map and the reﬁnement results were in good agreement with the
expected values. Hence the hydrogen atoms bonded to nitrogens
were isotropically reﬁned. Although some of the hydrogen atoms
could be identiﬁed in a Fourier difference map in the structures
of the complexes, in the ﬁnal model they were geometrically posi-
tioned and reﬁned using a riding model. All non-H atoms were re-
ﬁned anisotropically. Molecular graphics and packing ﬁgures were
obtained from Ortep [17] and Mercury [18], respectively.
2.4. Cytotoxicity and antitrypanosomal activity
2.4.1. Animals
Male BALB/c mice (6–8 weeks old) were raised at the animal
facilities of the Oswaldo Cruz Foundation (Rio de Janeiro, Brazil)
and maintained at the animal facilities of the Aggeu Magalhães Re-
search Center of the Oswaldo Cruz Foundation in Recife, Brazil. All
mice were sacriﬁced and treated in accordance with the Oswaldo
Cruz Foundation Commission for Experiments with Laboratory
Animals (Ministry of Health, Brazil, 0266/05).
2.4.2. Obtaining spleen cells
Spleen cells were obtained according to the literature [19]. After
euthanizing the animal with CO2 gas, the spleen of each mouse was
removed aseptically and placed in Falcon tubes containing RPMI
1640 with 10% of fetal calf serum (complete medium). In a vertical
ﬂow, each spleen was transferred to a Petri dish where they were
macerated. The obtained cell suspensions were transferred to Fal-
con tubes containing approximately 10 mL of incomplete medium,
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tant, distilled water was added to the sediment to promote lysis
of red blood cells. The supernatant, containing no cellular debris
was collected and centrifuged at 4 C, 200g for 5 min. The sediment
(containing cells) was resuspended in complete RPMI 1640. An ali-
quot of each cell suspension was separated, diluted in trypan blue
to be quantiﬁed in a Neubauer chamber and the cell viability was
determined.
2.4.3. In vitro cytotoxicity assay
The cytotoxicity of the compounds was determined using BALB/
c mice splenocytes (6  105 cells well1) cultured in 96-well plates
in RPMI 1640 media (Sigma Chemical Co., St. Louis, MO) supple-
mented with 10% of fetal calf serum (FCS; Cultilab, Campinas, SP,
Brazil) and 50 lg mL1 of gentamycin (Novafarma, Anápolis, GO,
Brazil). Each compound was evaluated in six concentrations (1, 5,
10, 25, 50 and 100 lg mL1), in triplicate on two independent as-
says. Cultures were incubated in the presence of 3H-thymidine
(Amersham Biosciences) (1 lCi well1) for 24 h at 37 C and 5%
CO2. After this period, the content of the plate was harvested to
determine the 3H-thymidine ([3H]TdR) incorporation using a
beta-radiation counter (b-matrix 9600, Packard). The cytotoxicity
of the compounds was determined by comparing the percentage
of 3H-thymidine incorporation (as an indicator of cell viability) of
imidazolidines-treated wells in relation to untreated wells. Non-
cytotoxic concentrations were deﬁned as those causing a reduction
of 3H-thymidine incorporation below 30% in relation to untreated
controls.
2.4.4. T. cruzi assays
Epimastigotes of T. cruzi (Y strain) were cultivated at 26 C in Li-
ver Infusion Tryptose medium (LIT) supplemented with 10% fetal
calf serum, 1% hemin, 1% R9 medium and 50 lg mL1 gentamycin.
Parasites (106 mL1) were cultured in a fresh medium in the ab-
sence or in the presence of the compounds being tested (from stock
solution in dimethylsulfoxide, DMSO). Cell growth was determined
after 11 days of culture by counting viable forms in a hemacytom-
eter, in triplicate. The compounds used were from a stock solution
in DMSO. To determine the IC50, cultures of Y strain epimastigotes
in the presence of different concentrations of the compounds were
evaluated after 11 days as described above. IC50 calculation was
carried out using non-linear regression on PRISM 4.0 GRAPHPAD
software. Y strain T. cruzi trypomastigotes were obtained from cul-
ture supernatants of Vero cell line at 37 C and placed in 96-well
plates (4  105 well1) in a RPMI 1640 medium supplemented
with 10% FCS and 50 lg mL1 gentamycin. Viable parasites were
counted in a hemacytometer 24 h after addition of complexes by
way of trypan blue exclusion. The percentage of inhibition was cal-
culated in relation to untreated cultures.3. Results and discussion
3.1. Formation of the antimony(III) complexes
Microanalyses and molar conductivity data are compatible with
the formation of [Sb(2Fo4Ph)Cl2] (1) and [Sb(2Ac4Ph)Cl2] (2), in
which an anionic thiosemicarbazone is attached to the metal cen-
ter together with two chloride ions.
3.2. Spectroscopic characterization
The vibrations attributed to m(C@N) at 1596 and 1588 cm1 in
the infrared spectra of H2Fo4Ph and H2Ac4Ph, respectively, shift
to 1611 and 1596 cm1 in the spectra of complexes (1) and (2),
in agreement with coordination of the imine nitrogen [13,20–22].The m(CS) absorption observed at 774 and 802 cm1 in the spectra
of the free thiosemicarbazones shifts to 730 and 753 cm1 in the
spectra of 1 and 2, indicating coordination of the sulfur. The 30–
50 cm1 shift is compatible with complexation of a thiolate sulfur
[13,20–23]. The in-plane deformation mode of the pyridine ring at
600 and 584 cm1 in the spectra of H2Fo4Ph and H2Ac4Ph, respec-
tively, shifts to 622 and 602 cm1 in complexes (1) and (2), sug-
gesting coordination of the hetero-aromatic nitrogen [13,20–23].
In the spectra of complexes 1 and 2 the absorptions at 453 and
505 cm1 and the absorptions at 432 and 430 cm1 were attrib-
uted to the m(SbANimine) and m(SbAS) vibrations, respectively,
and those at 225 and 222 cm1 to m(SbANpy) vibrations [13,20–
23]. Therefore in the complexes the thiosemicarbazones are at-
tached to the metal through the NpyANAS chelating system. One
absorption attributed to m(SbACl) at 344 and 327 cm1 was ob-
served in the spectra of 1 and 2, respectively [24].
The NMR spectra of the thiosemicarbazones and their anti-
mony(III) complexes were recorded in DMSO-d6. The 1H reso-
nances were assigned on the basis of chemical shifts and
multiplicities. The carbon type (C and CH) was determined by
using distortionless enhancement by polarization transfer (DEPT
135) experiments. The assignments of the protonated carbons
were made by 2D hetero-nuclear multiple quantum coherence
experiments (HMQC).
The signals of all hydrogens and carbons are duplicated in the
1H and 13C NMR spectra of the thiosemicarbazones, indicating
the presence of the Z and E conﬁgurational isomers in solution.
In the ﬁrst N(3)–H is hydrogen bonded to the hetero-aromatic
nitrogen while in the second N(3)–H is hydrogen bonded to the
solvent [13,20–23]. The signal of N(3)–H at d 14.43 and
12.04 ppm (H2Fo4Ph) and d 14.16 and 10.61 ppm (H2Ac4Ph) were
attributed to the Z and E isomers respectively [13,20–23]. The E
isomer corresponds to 96% and 88% for H2Fo4Ph and H2Ac4Ph,
respectively.
In the 1H and 13C NMR spectra of complexes (1–2) only one sig-
nal was observed for each hydrogen and each carbon. The absence
of the N(3)–H signal indicates coordination of an anionic thiosem-
icarbazone. The signals of all hydrogens undergo signiﬁcant shifts
in relation to their positions in the free bases. Similarly, the signals
of C@N, C@S and the pyridine carbons undergo signiﬁcant shifts,
indicating coordination of the thiosemicarbazones through the
NpyANAS chelating system (see Fig. 2), with adoption of the EZ
conformation in relation to the C7–N2 and N3–C8 bonds [13,20–
23].
3.3. X-ray diffraction analysis
Crystals of H2Fo4PhHCl were obtained from the ﬁltrate in the
syntheses of complex (1). Crystals of [Sb(2Fo4Ph)Cl2]2DMSO (1a)
and [Sb(2Ac4Ph)Cl2] (2) were obtained upon dissolution of 1 and
2, respectively, in DMSO.
Crystals’ data, data collection procedures, structures’ determi-
nation methods and reﬁnement results are summarized in Table 1.
Figs. 3 and 4 are perspective views of H2Fo4PhHCl and com-
plexes [Sb(2Fo4Ph)Cl2]2DMSO (1a) and [Sb(2Ac4Ph)Cl2] (2). Se-
lected intra-molecular bond distances and angles for H2Fo4Ph
HCl, [Sb(2Fo4Ph)Cl2]2DMSO (1a), H2Ac4Ph [25], [Sb(2Ac4Ph)Cl2]
(2) and [Sb(2Bz4Ph)Cl2] [13] are given in Tables 2 and 3. Molecular
structures of H2Ac4Ph and [Sb(2Bz4Ph)Cl2] have been determined
previously [25,13].
The pyridine nitrogen in H2Fo4PhHCl is protonated. The cation
adopts the EE conformation. The molecular packing of H2Fo4Ph
HCl (Fig. 5) reveals that the three N–H  Cl hydrogen bonds give
rise to a polymeric structure. The distances and angles observed
for H2Fo4PhHCl and H2Ac4Ph are very similar (see Tables 2 and
3). H2Ac4Ph adopts the EE conformation too, with two weak in-
Fig. 2. 13C NMR spectra of H2Ac4Ph (A) and [Sb(2Ac4Ph)Cl2] (2) (B).
Table 1
Crystal data and reﬁnement results for H2Fo4PhHCl, [Sb(2Fo4Ph)Cl2]2DMSO (1a) and [Sb(2Ac4Ph)Cl2] (2).
Compound H2Fo4PhHCl [Sb(2Fo4Ph)Cl2]2DMSO (1a) [Sb(2Ac4Ph)Cl2] (2)
Empirical formula C13H13ClN4S C17H17Cl2N4O2S3Sb C14H13Cl2N4SSb
Formula weight 292.78 598.18 461.99
T (K) 293(2) 293(2) 293(2)
Wavelength (Å) 0.71073 0.71073 0.71073
Crystal system orthorhombic monoclinic orthorhombic
Space group Pca2(1) P2(1)/c Pbca
a (Å) 7.6886(2) 12.1753(2) 8.2897(2)
b (Å) 13.9347(4) 21.6284(3) 14.7600(4)
c (Å) 13.0320(3) 9.25140(10) 27.7114(9)
b () 90 90.7200(10) 90
V (Å3) 1396.23(6) 2436.00(6) 3397.66(17)
Z 4 4 8
Dcalc (Mg/m3) 1.393 1.631 1.810
Absorption coefﬁcient (mm1) 0.414 1.629 2.066
F(0 0 0) 608 1184 1808
Crystal size 0.19  0.14  0.08 0.20  0.14  0.10 0.28  0.14  0.10
h Range () 2.92–26.37 2.90–26.37 2.76–26.37
Index ranges 7 6 h 6 10
19 6 k 6 13
17 6 l 6 15
15 6 h 6 14
25 6 k 6 27
11 6 l 6 11
10 6 h 6 10
18 6 k 6 18
34 6 l 6 34
Reﬂections collected/unique (Rint) 5256/2710(0.0200) 26,422/4978(0.0273) 36,227/3477(0.0504)
Data completeness to h = 26.37 99.9 % 99.9 % 100%
Absorption correction semi-empirical from equivalents semi-empirical from equivalents semi-empirical from equivalents
Data/restraints/parameters 2710/1/184 4978/6/294 3477/0/200
Absolute structure parameter 0.04(5)
Goodness-of-ﬁt (GOF) on F2 0.918 1.053 1.002
Final R indices (I > 2r(I)) R1 = 0.0256
wR2 = 0.0522
R1 = 0.0223
wR2 = 0.0615
R1 = 0.0265
wR2 = 0.0590
R indices (all data) R1 = 0.0346
wR2 = 0.0537
R1 = 0.0314
wR2 = 0.0630
R1 = 0.0424
wR2 = 0.0625
Largest difference in peak and hole (e Å3) 0.119 and 0.114 0.427 and 0.299 1.040 and 0.415
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[25].
In complexes (1a) and (2) Sb(III) is coordinated by a tridentate
anionic ligand and two chloride ions in a distorted square pyrami-
dal environment. The N(1)–Sb(1)–S(1) (ca. 145) and the Cl(2)–
Sb(1)–Cl(1) (ca. 162.8) angles from the base deviate markedlyfrom the ideal value of 180 in both complexes. The same distor-
tion was found in [Sb(2Bz4Ph)Cl2] (3) [13]. Some differences ob-
served for 3 could be due to the different temperatures of
measurement, 120 K for 3 and 293 K for complexes (1a) and (2).
However, this difference seems not to signiﬁcantly modify the re-
sults. The distances and angles of all three antimony complexes are
Fig. 3. Molecular plot of H2Fo4PhHCl showing the labeling scheme of the non-H atoms and their displacement ellipsoids at the 50% probability level.
Fig. 4. Molecular plot of [Sb(2Fo4Ph)Cl2]2DMSO (1a, A) and [Sb(2Ac4Ph)Cl2] (2, B) showing the labeling scheme of the non-H atoms and their displacement ellipsoids at the
50% probability level.
Table 2
Selected bond lengths for H2Fo4PhHCl, [Sb(2Fo4Ph)Cl2]2DMSO (1a), H2Ac4Ph, [Sb(2Ac4Ph)Cl2] (2) and [Sb(2Bz4Ph)Cl2] (3).
Atoms Bond lengths (Å)
H2Fo4PhHCl [Sb(2Fo4Ph)Cl2]2DMSO (1a) H2Ac4Ph[25]a [Sb(2Ac4Ph)Cl2] (2) [Sb(2Bz4Ph)Cl2][13] (3)a
Sb(1)–N(2) 2.247(2) 2.234(2) 2.252(3)
Sb(1)–N(1) 2.502(2) 2.356(3) 2.308(3)
Sb(1)–Cl(1) 2.5788(7) 2.5335(9) 2.5286(12)
Sb(1)–Cl(2) 2.5835(7) 2.6252(9) 2.6114(12)
Sb(1)–S(1) 2.5066(6) 2.5333(8) 2.5733(10)
S(1)–C(8) 1.665(2) 1.741(2) 1.677(2) 1.749(3) 1.725(4)
N(1)–C(6) 1.332(3) 1.324(3) 1.339(3) 1.329(4) 1.330(6)
N(1)–C(2) 1.341(2) 1.347(3) 1.334(2) 1.342(4) 1.341(6)
N(3)–C(8) 1.368(2) 1.318(3) 1.358(3) 1.308(4) 1.311(5)
N(2)–C(7) 1.281(2) 1.288(3) 1.284(3) 1.298(4) 1.301(5)
N(2)–N(3) 1.359(2) 1.371(3) 1.376(2) 1.367(3) 1.368(4)
a Numbering of some atoms in the published structure was modiﬁed in order to make discussion easier.
376 J.A. Lessa et al. / Polyhedron 30 (2011) 372–380very similar (see Tables 2 and 3). Fig. 6 shows the weak interac-
tions between Sb(III), N(4)–H and the O atoms of the solvent for
[Sb(2Fo4Ph)Cl2]2DMSO (1a).
The molecular packing of [Sb(2Ac4Ph)Cl2] (2) (see Fig. 7) reveals
that an inter-molecular short-contact occurs between Sb(III) and
Cl(2) (sum of van der Waals radii less 0.3 ÅA
0
) which gives rise to apseudo-octahedral environment. In this case the short-contact be-
tween Sb(III) and Cl(2) together with the N(4)–H hydrogen bond
give rise to a tri-dimensional network (see Table 4).
In the complexes the expected lengthening of the C(8)–S(1)
bonds from 1.665(2) Å in H2Fo4PhHCl to 1.741(2) Å in 1a and
from 1.677(2) Å in H2Ac4Ph [25] to 1.749(3) Å in 2, together with
Table 3
Selected bond angles for H2Fo4PhHCl, [Sb(2Fo4Ph)Cl2]2DMSO (1a), H2Ac4Ph, [Sb(2Ac4Ph)Cl2] (2) and [Sb(2Bz4Ph)Cl2] (3).
Atoms Angle ()
H2Fo4PhHCl [Sb(2Fo4Ph)Cl2]2DMSO (1a) H2Ac4Ph[25] [Sb(2Ac4Ph)Cl2] (2) [Sb(2Bz4Ph)Cl2][13] (3)
N(2)–Sb(1)–N(1) 68.80(6) 69.40(9) 70.31(12)
N(1)–Sb(1)–Cl(2) 83.97(5) 83.45(7)
N(1)–Sb(1)–S(1) 145.08(5) 145.73(6) 144.82(10)
N(2)–Sb(1)–Cl(1) 79.92(5) 84.43(7)
Cl(2)–Sb(1)–Cl(1) 162.82(3) 162.78(3) 158.55(4)
N(2)–Sb(1)–Cl(2) 83.84(5) 81.40(7) 83.26(9)
N(2)–Sb(1)–S(1) 76.40(5) 76.47(6) 74.51(8)
Cl(2)–Sb(1)–S(1) 89.69(2) 91.36(3)
N(1)–Sb(1)–Cl(1) 84.96(5) 82.44(7)
S(1)–Sb(1)–Cl(1) 91.90(2) 94.77(3)
N(1)–C(2)–C(7) 118.55(16) 115.9(2) 116.21(3) 114.6(3) 115.3(3)
C(2)–C(7)–N(2) 118.68(16) 120.7(2) 114.93(2) 116.8(3) 117.4(4)
C(7)–N(2)–N(3) 116.98(15) 115.3(2) 118.8(2) 115.9(2) 115.4(3)
C(8)–N(3)–N(2) 121.31(16) 115.7(2) 118.9(2) 116.7(2) 116.0(3)
N(3)–C(8)–S(1) 116.59(14) 126.2(2) 119.7(1) 126.1(2) 126.1(3)
S(1)–C(8)–N(4) 127.86(13) 115.1(2) 125.5(2) 115.1(2) 115.6(3)
N(3)–C(8)–N(4) 115.69(14) 118.8(2) 114.8(2) 118.8(3) 118.2(3)
C(8)–N(4)–C(9) 128.77(15) 130.2(2) 127.6(2) 129.9(3) 130.2(4)
Fig. 5. Molecular packing of H2Fo4PhHCl.
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H2Fo4PhHCl to 1.318(3) Å in 1a and 1.358(3) H2Ac4Ph to
1.308(4) Å in 2, were observed. Therefore, the C(8)–S(1) bond
changes from a double to a predominantly single bond whereas
N(3)–C(8) acquires some double bond character.
The bond distances between antimony and the imine nitrogen,
2.247(2) Å in 1a and 2.234(2) Å in 2, are shorter than the distance
between antimony and the pyridine nitrogen, 2.502(2) Å in 1a and
2.356(3) Å in 2. In 2 the Sb(1)–Cl(1) bond is shorter than the Sb(1)–
Cl(2) bond probably due to the presence of a short-contact interac-
tion between Cl(2) from one molecule and the antimony of a
neighbor molecule (see Table 2 and Fig. 7).
A twisting of approximately 180 in the N(3)–C(8) bond of the
thiosemicarbazones to match the steric requirements of tridentate
coordination was evidenced. Hence, some angles undergo signiﬁ-
cant changes on complexation. The C(8)–N(3)–N(2) angle goes
from 121.31(16) in H2Fo4PhHCl to 115.7(2) in 1a and from
118.9(2) in H2Ac4Ph [25] to 116.7(2) in 2; N(3)–C(8)–S(1) goes
from 116.59(14) in H2Fo4PhHCl to 126.2(2) in 1a and
119.7(1) in H2Ac4Ph [25] to 126.1(2) in 2; N(4)–C(8)–S(1) variesfrom 127.86(13) in the free base to 115.1(2) in 1a and 125.5(2)
in H2Ac4Ph [25] to 115.1(2) in 2.
3.4. Antitrypanosomal activity
Table 5 reports the cytotoxicities and the IC50 values for growth
inhibition induced by the studied compounds, on trypomastigote
and epimastigote forms of T. cruzi. Dose–response curves were ob-
tained in all cases but in some cases we were unable to determine
the IC50 values.
H2Fo4Ph proved to be highly cytotoxic. We could not determine
its IC50 value against both forms of the parasitic cycle. Its anti-
mony(III) complex (1) exhibited growth inhibition activity against
both trypomastigote and epimastigote forms ofT. cruziwith similar
values of IC50 (1.2 lM), which were lower than the IC50 determined
for benznidazole and nifurtimox against both forms. However it re-
vealed to be cytotoxic at approximately the same dose (1 lM).
H2Ac4Ph was active against the epimastigote form at high
doses (IC50 = 52.8 lM), being cytotoxic at concentrations lower
than 1 lM. Complex (2) was active at low doses (IC50 = 1.23 lM)
Fig. 6. Short-contacts of [Sb(2Fo4Ph)Cl2]2DMSO (1a).
Fig. 7. Molecular packing of [Sb(2Ac4Ph)Cl2] (2).
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Table 4
Hydrogen bonds distances (Å) and angles () for H2Fo4PhHCl, [Sb(2Fo4Ph)Cl2]2DMSO (1a) and [Sb(2Ac4Ph)Cl2] (2).
D–H  A d(D–H) d(H  A) d(D  A) (D–H  A) Symmetry operationa
H2Fo4PhHCl N(3)–H(3A)  Cl(1) 0.81(2) 2.45(2) 3.2572(18) 171.6(17) [x + 3/2, y, z  1/2]
N(4)–H(4A)  Cl(1) 0.884(18) 2.641(19) 3.4904(16) 161.4(15) intra-molecular
N(1)–H(1A)  Cl(1) 0.92(2) 2.13 3.0125(16) 161.1(18) intra-molecular
[Sb(2Fo4Ph)Cl2]2DMSO (1a) N(4)–H(4A)  O(3A) 0.86 2.014 2.850(3) 163.8 [x, y, z + 1]
[Sb(2Ac4Ph)Cl2] (2) N(4)–H(4A)  Cl(1) 0.86 2.54 3.314(3) 150.5 [x + 1/2, y  1, z]
a The symmetry transformations used to generate equivalent atoms are bracketed.
Table 5
Antitrypanosomal activity of H2Fo4Ph, H2Ac4Ph and H2Bz4Ph, their Sb(III) com-
plexes, antimony chloride and the reference compounds benznidazole (bnz) and
nifurtimox (nfx).
Compound Cytotoxicityb
(lmol L1)
IC50 trypoa
(lmol L1)
IC50 epia
(lmol L1)
H2Fo4Ph <1 ND ND
[Sb(2Fo4Ph)Cl2] (1) <1 1.27 1.23
H2Ac4Ph <1 ND 52.78
[Sb(2Ac4Ph)Cl2] (2) <1 1.23 ND
H2Bz4Ph <3.00 14.41 ND
[Sb(2Bz4Ph)Cl2] (3) <1.91 8.39 2.10
SbCl3 <4.38 65.75 6.79
bnz 96.06 6.26 6.65
nfx 3.48 2.75 1.88
bnz = benznidazole; nfx = nifurtimox; ND = not determined; ND (‘‘Not Deter-
mined’’): data of activity were acquired in a dose–response curve but no linear
regression was obtained from the curves.
a Calculated at seven concentrations using data obtained from at least three
independent experiments, with a SD less than 10% in all cases.
b Expressed as the highest concentration tested that was not cytotoxic for the
BALB/c mice splenocytes. Calculated at six concentrations using data obtained from
at least three independent experiments, with a SD less than 10% in all cases. Values
in M are showed in parentheses.
J.A. Lessa et al. / Polyhedron 30 (2011) 372–380 379against the bloodstream trypomastigote form, being more active
than both nifurtimox and benznidazole. Nevertheless it proved to
be cytotoxic at doses lower than 1 lM.
H2Bz4Ph was moderately active against the infecting trypomas-
tigote form (IC50 = 14.41 lM) while its cytotoxicity was lower than
those of all other thiosemicarbazones. Complex (3) proved to be
more active against the epimastigote (IC50 = 2.10 lM) than against
the trypomastigote form (IC50 = 8.39 lM); its cytotoxicity was the
lowest among all ligands and complexes.
The antimony salt SbCl3 was more active against the prolifera-
tive epimastigote form than against the trypomastigote form, but
high doses were required for the inhibition of trypomastigotes’
growth. As a consequence, its cytotoxicity was the lowest among
all studied compounds.
The antimony complexes proved to have antitrypanosomal
activity. In all cases activity is higher than that of the starting salt.
Complexes (1) and (2) were more active than the reference drugs
nifurtimox and benznidazole. However the studied compounds
did not reveal to be good as antitrypanosomal drug candidates
mainly due to their cytotoxicities. It is worth mentioning that the
determined values of IC50 for nifurtimox demonstrated that it
was more active against the more susceptible epimastigote form
and that its cytotoxic effects occur at doses slightly higher to those
effective in the inhibition of the parasite growth.4. Conclusions
The antimony(III) complexes presented antitrypanosomal activ-
ity against the epimastigote and trypomastigote forms of T. cruzi.
Some of the compounds exhibited higher activity than the refer-
ence drugs nifurtimox and benznidazole. However the studiedcompounds presented cytotoxicity at doses lower than their IC50
values, suggesting that they are not good as new antitrypanosomal
drug candidates.
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